- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Statin use tied to lower risk of acute-on-chronic liver failure in cirrhosis patients: Study
USA: Statin use is significantly associated with reduced development of high-grade acute-on-chronic liver failure (ACLF) in patients with cirrhosis, according to results from a large, retrospective, cohort study. The study appears in the Journal of Hepatology.
Considering the need to identify therapies that prevent the development of CLF in cirrhosis patients, Nadim Mahmud, Department of Medicine, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA, and colleagues aimed to evaluate the association between statin exposure and the risk of developing ACLF in a large national cohort of patients with cirrhosis.
For this purpose, the researchers performed a retrospective cohort study of patients diagnosed with cirrhosis within the Veterans Health Administration between 2008 and 2018. Based on statin exposure, patients were stratified into 3 groups -- statin naïve, existing statin users, and new statin initiators. To comprehensively address potential confounding in estimating the association between time-updated statin exposure and the first occurrence of high-grade ACLF, Cox proportional hazards regression models with inverse probability treatment weighting and marginal structural models were utilized.
Based on the study, the researchers reported the following findings:
· The cohort included 84,963 patients, of whom 26.9% were on a statin at baseline.
· A total of 8,558 (10.1%) patients with cirrhosis were hospitalized with high-grade ACLF over a median follow-up time of 51.6 months.
· Time-updated statin use was associated with a significant reduction in the hazard of developing ACLF (hazard ratio [HR] 0.62).
· Increasing doses of statin were associated with a progressively reduced hazard of developing ACLF (HR 0.75 for <20 mg vs. 0 mg of time-updated statin exposure, in simvastatin equivalents; HR 0.61 for >20 mg vs. 0 mg statin exposure).
· Every additional 5 months of statin exposure was associated with a 9% reduced hazard of high-grade ACLF (HR 0.91).
To conclude, "the results of this study support the promising role that statins may play in future prevention of acute-on-chronic liver failure in patients with cirrhosis."
Reference:
Mahmud N, Chapin S, Goldberg DS, Reddy KR, Taddei TH, Kaplan DE. Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort. J Hepatol. 2022 May;76(5):1100-1108. doi: 10.1016/j.jhep.2021.12.034. Epub 2022 Jan 21. PMID: 35066085; PMCID: PMC9018495.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751